Details of the Drug

General Information of Drug (ID: DM3PD2C)

Drug Name
Fluoxetine
Synonyms
Eufor; Floxetine; Fluoxetin; Fluoxetina; Fluoxetinum; Fluval; Fontex; Portal; Pulvules; Reconcile; Reneuron; Fluoxetina [Spanish]; Fluoxetine Hcl; Prozac Weekly; Animex-On; Fluoxetina [INN-Spanish]; Fluoxetine (Prozac); Fluoxetine (TN); Fluoxetinum [INN-Latin]; Lilly-110140; Prozac (TN); Fluoxetine (USAN/INN); Fluoxetine [USAN:INN:BAN]; N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine; N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; Dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine; (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine;(+/-)-Fluoxetine; (+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; (+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]; (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [1], [2]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 309.33
Topological Polar Surface Area (xlogp) 4
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
60% of drug becomes completely available to its intended biological destination(s) [4]
Elimination
1.25% of drug is excreted from urine in the unchanged form [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 4.29956 micromolar/kg/day [5]
Water Solubility
The ability of drug to dissolve in water is measured as 15.2 mg/mL [3]
Chemical Identifiers
Formula
C17H18F3NO
IUPAC Name
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
Canonical SMILES
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F
InChI
InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3
InChIKey
RTHCYVBBDHJXIQ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3386
ChEBI ID
CHEBI:86990
CAS Number
54910-89-3
DrugBank ID
DB00472
TTD ID
D0TR5X
VARIDT ID
DR00459
INTEDE ID
DR0720
ACDINA ID
D00283

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Modulator [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [8]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [9]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [10]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [11]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [12]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [13]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [10]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Depression
ICD Disease Classification 6A70-6A7Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Serotonin transporter (SERT) DTT SLC6A4 8.76E-01 7.18E-05 6.19E-04
P-glycoprotein 1 (ABCB1) DTP P-GP 6.54E-01 1.95E-01 4.04E-01
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 9.45E-02 -1.86E-01 -9.83E-01
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 4.32E-01 4.39E-02 4.30E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 8.46E-01 -6.63E-03 -4.49E-02
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.57E-01 9.43E-03 1.29E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 9.62E-01 2.57E-02 1.10E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 8.70E-01 2.98E-02 1.22E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 2.35E-01 2.78E-02 2.09E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.76E-01 1.26E-01 8.27E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Fluoxetine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Sertraline. Depression [6A70-6A7Z] [95]
Trimipramine DM1SC8M Major Additive serotonergic effects by the combination of Fluoxetine and Trimipramine. Depression [6A70-6A7Z] [96]
Cyclobenzaprine DM1YBRM Major Additive serotonergic effects by the combination of Fluoxetine and Cyclobenzaprine. Depression [6A70-6A7Z] [97]
Nortriptyline DM4KDYJ Major Additive serotonergic effects by the combination of Fluoxetine and Nortriptyline. Depression [6A70-6A7Z] [96]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Fluoxetine and Vilazodone. Depression [6A70-6A7Z] [98]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Fluoxetine and Nefazodone. Depression [6A70-6A7Z] [98]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Fluoxetine and Selegiline. Depression [6A70-6A7Z] [99]
Vortioxetine DM6F1PU Major Decreased metabolism of Fluoxetine caused by Vortioxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [100]
Duloxetine DM9BI7M Major Additive serotonergic effects by the combination of Fluoxetine and Duloxetine. Depression [6A70-6A7Z] [98]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Fluoxetine and Isocarboxazid. Depression [6A70-6A7Z] [99]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Fluoxetine and Milnacipran. Depression [6A70-6A7Z] [98]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Fluoxetine and Escitalopram. Depression [6A70-6A7Z] [101]
Tranylcypromine DMGB5RE Major Additive serotonergic effects by the combination of Fluoxetine and Tranylcypromine. Depression [6A70-6A7Z] [99]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Fluoxetine and Desvenlafaxine. Depression [6A70-6A7Z] [98]
OPC-34712 DMHG57U Major Decreased metabolism of Fluoxetine caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [102]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Fluoxetine and Phenelzine. Depression [6A70-6A7Z] [99]
Clomipramine DMINRKW Major Decreased metabolism of Fluoxetine caused by Clomipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [96]
Trazodone DMK1GBJ Major Additive serotonergic effects by the combination of Fluoxetine and Trazodone. Depression [6A70-6A7Z] [98]
Amoxapine DMKITQE Major Decreased metabolism of Fluoxetine caused by Amoxapine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [96]
Doxepin DMPI98T Major Decreased metabolism of Fluoxetine caused by Doxepin mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [103]
Maprotiline DMPWB7T Major Additive serotonergic effects by the combination of Fluoxetine and Maprotiline. Depression [6A70-6A7Z] [98]
⏷ Show the Full List of 21 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Fluoxetine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Fluoxetine and Methylene blue. Acquired methaemoglobinaemia [3A93] [97]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Fluoxetine and Repaglinide. Acute diabete complication [5A2Y] [104]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Fluoxetine and Glibenclamide. Acute diabete complication [5A2Y] [104]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Fluoxetine and Tolazamide. Acute diabete complication [5A2Y] [104]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Fluoxetine and Nateglinide. Acute diabete complication [5A2Y] [104]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Fluoxetine and Insulin-glulisine. Acute diabete complication [5A2Y] [104]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Fluoxetine and Insulin-aspart. Acute diabete complication [5A2Y] [105]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Fluoxetine and Glipizide. Acute diabete complication [5A2Y] [104]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Fluoxetine and Ivosidenib. Acute myeloid leukaemia [2A60] [106]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Midostaurin. Acute myeloid leukaemia [2A60] [95]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Idarubicin. Acute myeloid leukaemia [2A60] [95]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Daunorubicin. Acute myeloid leukaemia [2A60] [95]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Arn-509. Acute myeloid leukaemia [2A60] [107]
Oliceridine DM6MDCF Major Decreased metabolism of Fluoxetine caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [108]
Galantamine DMEO794 Moderate Decreased metabolism of Fluoxetine caused by Galantamine mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [109]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Fluoxetine and Rivastigmine. Alzheimer disease [8A20] [95]
Donepezil DMIYG7Z Minor Decreased metabolism of Fluoxetine caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [110]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Fluoxetine and Metronidazole. Amoebiasis [1A36] [111]
Inotersen DMJ93CT Moderate Increased risk of bleeding by the combination of Fluoxetine and Inotersen. Amyloidosis [5D00] [112]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Fluoxetine and Ivabradine. Angina pectoris [BA40] [107]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Fluoxetine and Bepridil. Angina pectoris [BA40] [95]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Fluoxetine and Dronedarone. Angina pectoris [BA40] [95]
Nifedipine DMSVOZT Moderate Decreased metabolism of Fluoxetine caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [95]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Fluoxetine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [113]
Buspirone DMBS632 Major Additive serotonergic effects by the combination of Fluoxetine and Buspirone. Anxiety disorder [6B00-6B0Z] [98]
Methylphenobarbital DMDSWAG Moderate Antagonize the effect of Fluoxetine when combined with Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [114]
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Fluoxetine and Cilostazol. Arterial occlusive disease [BD40] [112]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Voriconazole. Aspergillosis [1F20] [95]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Posaconazole. Aspergillosis [1F20] [95]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Fluoxetine and Levalbuterol. Asthma [CA23] [115]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Fluoxetine and Terbutaline. Asthma [CA23] [116]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Pirbuterol. Asthma [CA23] [116]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Fluoxetine and Salbutamol. Asthma [CA23] [115]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Fluoxetine and Formoterol. Asthma [CA23] [116]
Desipramine DMT2FDC Major Additive serotonergic effects by the combination of Fluoxetine and Desipramine. Attention deficit hyperactivity disorder [6A05] [96]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Ofloxacin. Bacterial infection [1A00-1C4Z] [117]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [95]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Fluoxetine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [118]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Fluoxetine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [95]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Fluoxetine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [117]
Linezolid DMGFPU2 Major Additive serotonergic effects by the combination of Fluoxetine and Linezolid. Bacterial infection [1A00-1C4Z] [119]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [117]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Levofloxacin. Bacterial infection [1A00-1C4Z] [117]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Fluoxetine caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [118]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [95]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Telithromycin. Bacterial infection [1A00-1C4Z] [95]
Retigabine DMGNYIH Moderate Antagonize the effect of Fluoxetine when combined with Retigabine. Behcet disease [4A62] [120]
Lamotrigine DM8SXYG Moderate Antagonize the effect of Fluoxetine when combined with Lamotrigine. Bipolar disorder [6A60] [120]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Loperamide. Bowel habit change [ME05] [121]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Eribulin. Breast cancer [2C60-2C6Y] [95]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Lapatinib. Breast cancer [2C60-2C6Y] [95]
Alpelisib DMEXMYK Moderate Increased metabolism of Fluoxetine caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [122]
Tamoxifen DMLB0EZ Major Decreased metabolism of Fluoxetine caused by Tamoxifen mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [123]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Fluoxetine and Toremifene. Breast cancer [2C60-2C6Y] [95]
Mannitol DMSCDY9 Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Mannitol. Bronchiectasis [CA24] [114]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Fluoxetine and Sotalol. Cardiac arrhythmia [BC9Z] [95]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [124]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Fluoxetine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [116]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Fluoxetine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [115]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Fluoxetine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [116]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Fluoxetine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [116]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Fluoxetine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [116]
Phenylbutazone DMAYL0T Moderate Increased risk of bleeding by the combination of Fluoxetine and Phenylbutazone. Chronic pain [MG30] [112]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Fluoxetine and Dihydrocodeine. Chronic pain [MG30] [125]
Ketoprofen DMRKXPT Moderate Increased risk of bleeding by the combination of Fluoxetine and Ketoprofen. Chronic pain [MG30] [112]
Levetiracetam DMTGDN8 Moderate Antagonize the effect of Fluoxetine when combined with Levetiracetam. Chronic pain [MG30] [120]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Fluoxetine and Levomilnacipran. Chronic pain [MG30] [98]
Anisindione DM2C48U Moderate Decreased metabolism of Fluoxetine caused by Anisindione mediated inhibition of CYP450 enzyme. Coagulation defect [3B10] [126]
Regorafenib DMHSY1I Moderate Increased risk of bleeding by the combination of Fluoxetine and Regorafenib. Colorectal cancer [2B91] [112]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Oxaliplatin. Colorectal cancer [2B91] [95]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Fluoxetine and Isoproterenol. Conduction disorder [BC63] [115]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Fluoxetine and Olopatadine. Conjunctiva disorder [9A60] [127]
Methohexital DM7YMIT Minor Decreased metabolism of Fluoxetine caused by Methohexital mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [126]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Halothane. Corneal disease [9A76-9A78] [95]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Propofol. Corneal disease [9A76-9A78] [128]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Sevoflurane. Corneal disease [9A76-9A78] [95]
Thiopental DMGP8AX Minor Decreased metabolism of Fluoxetine caused by Thiopental mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [126]
Alfentanil DMVO0UB Major Additive serotonergic effects by the combination of Fluoxetine and Alfentanil. Corneal disease [9A76-9A78] [98]
Remifentanil DMZTXCH Major Additive serotonergic effects by the combination of Fluoxetine and Remifentanil. Corneal disease [9A76-9A78] [98]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Probucol. Coronary atherosclerosis [BA80] [95]
Ardeparin DMYRX8B Moderate Increased risk of bleeding by the combination of Fluoxetine and Ardeparin. Coronary thrombosis [BA43] [112]
Dextromethorphan DMUDJZM Major Decreased metabolism of Fluoxetine caused by Dextromethorphan mediated inhibition of CYP450 enzyme. Cough [MD12] [129]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Clofazimine. Crohn disease [DD70] [130]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Fluoxetine and Mifepristone. Cushing syndrome [5A70] [95]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Fluoxetine and Pasireotide. Cushing syndrome [5A70] [95]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Osilodrostat. Cushing syndrome [5A70] [107]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Fluoxetine and Ethanol. Cystitis [GC00] [127]
Danaparoid DM6CLBN Moderate Increased risk of bleeding by the combination of Fluoxetine and Danaparoid. Deep vein thrombosis [BD71] [112]
Rivaroxaban DMQMBZ1 Moderate Increased risk of bleeding by the combination of Fluoxetine and Rivaroxaban. Deep vein thrombosis [BD71] [112]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Fluoxetine and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [131]
Tetrabenazine DMYWQ0O Major Decreased metabolism of Fluoxetine caused by Tetrabenazine mediated inhibition of CYP450 enzyme. Dissociative neurological symptom disorder [6B60] [132]
Deutetrabenazine DMUPFLI Major Decreased metabolism of Fluoxetine caused by Deutetrabenazine mediated inhibition of CYP450 enzyme. Dystonic disorder [8A02] [133]
Ingrezza DMVPLNC Major Decreased metabolism of Fluoxetine caused by Ingrezza mediated inhibition of CYP450 enzyme. Dystonic disorder [8A02] [134]
Fenfluramine DM0762O Major Additive serotonergic effects by the combination of Fluoxetine and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [98]
Zonisamide DM0DTF7 Moderate Antagonize the effect of Fluoxetine when combined with Zonisamide. Epilepsy/seizure [8A61-8A6Z] [120]
Primidone DM0WX6I Moderate Antagonize the effect of Fluoxetine when combined with Primidone. Epilepsy/seizure [8A61-8A6Z] [120]
Felbamate DM1V5ZS Moderate Antagonize the effect of Fluoxetine when combined with Felbamate. Epilepsy/seizure [8A61-8A6Z] [120]
Oxcarbazepine DM5PU6O Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Oxcarbazepine. Epilepsy/seizure [8A61-8A6Z] [120]
Mephenytoin DM5UGDK Moderate Decreased metabolism of Fluoxetine caused by Mephenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [135]
Methsuximide DM6L5VO Moderate Antagonize the effect of Fluoxetine when combined with Methsuximide. Epilepsy/seizure [8A61-8A6Z] [120]
Gabapentin DM6T924 Moderate Antagonize the effect of Fluoxetine when combined with Gabapentin. Epilepsy/seizure [8A61-8A6Z] [120]
Ethosuximide DMDZ9LT Moderate Antagonize the effect of Fluoxetine when combined with Ethosuximide. Epilepsy/seizure [8A61-8A6Z] [120]
Tiagabine DMKSQG0 Moderate Antagonize the effect of Fluoxetine when combined with Tiagabine. Epilepsy/seizure [8A61-8A6Z] [120]
Stiripentol DMMSDOY Moderate Decreased metabolism of Fluoxetine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [107]
Phenacemide DMOHS9P Moderate Antagonize the effect of Fluoxetine when combined with Phenacemide. Epilepsy/seizure [8A61-8A6Z] [120]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Fluoxetine caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [135]
Paramethadione DMR5ZUP Moderate Antagonize the effect of Fluoxetine when combined with Paramethadione. Epilepsy/seizure [8A61-8A6Z] [120]
Brivaracetam DMSEPK8 Moderate Antagonize the effect of Fluoxetine when combined with Brivaracetam. Epilepsy/seizure [8A61-8A6Z] [120]
Lacosamide DMVM6QR Moderate Antagonize the effect of Fluoxetine when combined with Lacosamide. Epilepsy/seizure [8A61-8A6Z] [120]
Rufinamide DMWE60C Moderate Antagonize the effect of Fluoxetine when combined with Rufinamide. Epilepsy/seizure [8A61-8A6Z] [120]
Ethotoin DMXWOCP Moderate Decreased metabolism of Fluoxetine caused by Ethotoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [135]
Phenobarbital DMXZOCG Moderate Antagonize the effect of Fluoxetine when combined with Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [120]
Vigabatrin DMYT0OG Moderate Antagonize the effect of Fluoxetine when combined with Vigabatrin. Epilepsy/seizure [8A61-8A6Z] [120]
Carbamazepine DMZOLBI Moderate Decreased metabolism of Fluoxetine caused by Carbamazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [136]
Eslicarbazepine DMZREFQ Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [120]
Cannabidiol DM0659E Minor Decreased metabolism of Fluoxetine caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [107]
Ethacrynic acid DM60QMR Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Ethacrynic acid. Essential hypertension [BA00] [114]
Nicardipine DMCDYW7 Moderate Decreased metabolism of Fluoxetine caused by Nicardipine mediated inhibition of CYP450 enzyme. Essential hypertension [BA00] [95]
Benzthiazide DMQWZ0H Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Benzthiazide. Essential hypertension [BA00] [114]
Mefenamic acid DMK7HFI Moderate Increased risk of bleeding by the combination of Fluoxetine and Mefenamic acid. Female pelvic pain [GA34] [112]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Fluoxetine and Tazemetostat. Follicular lymphoma [2A80] [112]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Solifenacin. Functional bladder disorder [GC50] [95]
Mirabegron DMS1GYT Moderate Decreased metabolism of Fluoxetine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [137]
Tolterodine DMSHPW8 Minor Decreased metabolism of Fluoxetine caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [138]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Fluoxetine caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [139]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Pentamidine. Fungal infection [1F29-1F2F] [95]
Terbinafine DMI6HUW Moderate Decreased metabolism of Fluoxetine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [140]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Ketoconazole. Fungal infection [1F29-1F2F] [95]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Fluoxetine and Cisapride. Gastro-oesophageal reflux disease [DA22] [95]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [95]
Avapritinib DMK2GZX Moderate Increased risk of bleeding by the combination of Fluoxetine and Avapritinib. Gastrointestinal stromal tumour [2B5B] [112]
Acetazolamide DM1AF5U Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Acetazolamide. Glaucoma [9C61] [114]
Methazolamide DM7J2TA Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Methazolamide. Glaucoma [9C61] [114]
Dichlorphenamide DMH7IDQ Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Dichlorphenamide. Glaucoma [9C61] [114]
Sulfinpyrazone DMEV954 Moderate Increased risk of bleeding by the combination of Fluoxetine and Sulfinpyrazone. Gout [FA25] [112]
Carvedilol DMHTEAO Moderate Decreased metabolism of Fluoxetine caused by Carvedilol mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [123]
Chlorothiazide DMLHESP Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Chlorothiazide. Heart failure [BD10-BD1Z] [114]
Furosemide DMMQ8ZG Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Furosemide. Heart failure [BD10-BD1Z] [114]
Amiloride DMRTSGP Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Amiloride. Heart failure [BD10-BD1Z] [114]
Bumetanide DMRV7H0 Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Bumetanide. Heart failure [BD10-BD1Z] [114]
Hydroflumethiazide DMVPUQI Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Hydroflumethiazide. Heart failure [BD10-BD1Z] [114]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Fluoxetine and Procarbazine. Hodgkin lymphoma [2B30] [99]
MK-1439 DM215WE Minor Decreased metabolism of Fluoxetine caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [141]
Cobicistat DM6L4H2 Moderate Decreased clearance of Fluoxetine due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [142]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Fluoxetine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [143]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Fluoxetine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [144]
Etravirine DMGV8QU Moderate Decreased metabolism of Fluoxetine caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [145]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [95]
Ritonavir DMU764S Moderate Decreased metabolism of Fluoxetine caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [146]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Fluoxetine caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [147]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Fluoxetine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [111]
Nebivolol DM7F1PA Moderate Decreased metabolism of Fluoxetine caused by Nebivolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [123]
Levamlodipine DM92S6N Moderate Decreased metabolism of Fluoxetine caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [95]
Verapamil DMA7PEW Moderate Decreased metabolism of Fluoxetine caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [95]
Indapamide DMGN1PW Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Indapamide. Hypertension [BA00-BA04] [114]
Trichlormethiazide DMHAQCO Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Trichlormethiazide. Hypertension [BA00-BA04] [114]
Labetalol DMK8U72 Moderate Decreased metabolism of Fluoxetine caused by Labetalol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [123]
Felodipine DMOSW35 Moderate Decreased metabolism of Fluoxetine caused by Felodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [95]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Hydrochlorothiazide. Hypertension [BA00-BA04] [114]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Fluoxetine and Dipyridamole. Hypertension [BA00-BA04] [112]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Fluoxetine caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [107]
Givosiran DM5PFIJ Moderate Decreased metabolism of Fluoxetine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [148]
Meclofenamic acid DM05FXR Moderate Increased risk of bleeding by the combination of Fluoxetine and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [149]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Fluoxetine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [150]
Amobarbital DM0GQ8N Minor Decreased metabolism of Fluoxetine caused by Amobarbital mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [126]
Propiomazine DMKY8V1 Moderate Additive antidopaminergic effects by the combination of Fluoxetine and Propiomazine. Insomnia [7A00-7A0Z] [151]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Fluoxetine and Polyethylene glycol. Irritable bowel syndrome [DD91] [95]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Fluoxetine and Phenolphthalein. Irritable bowel syndrome [DD91] [95]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Fluoxetine caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [152]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Fluoxetine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [107]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Fluoxetine and Crizotinib. Lung cancer [2C25] [153]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Fluoxetine and Porfimer Sodium. Lung cancer [2C25] [154]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Fluoxetine and Ceritinib. Lung cancer [2C25] [95]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Fluoxetine caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [155]
PF-06463922 DMKM7EW Moderate Increased metabolism of Fluoxetine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [111]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Fluoxetine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [156]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Fluoxetine and Osimertinib. Lung cancer [2C25] [157]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Fluoxetine and Selpercatinib. Lung cancer [2C25] [107]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Fluoxetine and Lumefantrine. Malaria [1F40-1F45] [111]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Fluoxetine and Halofantrine. Malaria [1F40-1F45] [158]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Fluoxetine and Chloroquine. Malaria [1F40-1F45] [159]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Fluoxetine and Hydroxychloroquine. Malaria [1F40-1F45] [159]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Primaquine. Malaria [1F40-1F45] [95]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [107]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Fluoxetine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [160]
Acalabrutinib DM7GCVW Moderate Increased risk of bleeding by the combination of Fluoxetine and Acalabrutinib. Mature B-cell lymphoma [2A85] [112]
Ibrutinib DMHZCPO Moderate Increased risk of bleeding by the combination of Fluoxetine and Ibrutinib. Mature B-cell lymphoma [2A85] [112]
Ponatinib DMYGJQO Moderate Increased risk of bleeding by the combination of Fluoxetine and Ponatinib. Mature B-cell lymphoma [2A85] [112]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Fluoxetine and Vemurafenib. Melanoma [2C30] [95]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and LGX818. Melanoma [2C30] [161]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Fluoxetine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [162]
Propranolol DM79NTF Moderate Decreased metabolism of Fluoxetine caused by Propranolol mediated inhibition of CYP450 enzyme. Migraine [8A80] [123]
Almogran DM7I64Z Major Additive serotonergic effects by the combination of Fluoxetine and Almogran. Migraine [8A80] [98]
Frovatriptan DM7RE8P Major Additive serotonergic effects by the combination of Fluoxetine and Frovatriptan. Migraine [8A80] [98]
Rizatriptan DMDJMA3 Major Additive serotonergic effects by the combination of Fluoxetine and Rizatriptan. Migraine [8A80] [98]
Naratriptan DMO50U2 Major Additive serotonergic effects by the combination of Fluoxetine and Naratriptan. Migraine [8A80] [98]
Sumatriptan DMVYXR8 Major Additive serotonergic effects by the combination of Fluoxetine and Sumatriptan. Migraine [8A80] [98]
Exjade DMHPRWG Moderate Increased risk of bleeding by the combination of Fluoxetine and Exjade. Mineral absorption/transport disorder [5C64] [112]
Flibanserin DM70DTN Moderate Decreased metabolism of Fluoxetine caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [163]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Fluoxetine and Panobinostat. Multiple myeloma [2A83] [164]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Fluoxetine and Thalidomide. Multiple myeloma [2A83] [165]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Fluoxetine and Siponimod. Multiple sclerosis [8A40] [111]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Fluoxetine and Fingolimod. Multiple sclerosis [8A40] [95]
Ozanimod DMT6AM2 Major Additive serotonergic effects by the combination of Fluoxetine and Ozanimod. Multiple sclerosis [8A40] [166]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Romidepsin. Mycosis fungoides [2B01] [95]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Fluoxetine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [107]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Fluoxetine and Nilotinib. Myeloproliferative neoplasm [2A20] [95]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Fluoxetine and Ruxolitinib. Myeloproliferative neoplasm [2A20] [112]
Imatinib DM7RJXL Moderate Decreased metabolism of Fluoxetine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [167]
Dasatinib DMJV2EK Moderate Increased risk of bleeding by the combination of Fluoxetine and Dasatinib. Myeloproliferative neoplasm [2A20] [112]
Prasugrel DM7MT6E Moderate Increased risk of bleeding by the combination of Fluoxetine and Prasugrel. Myocardial infarction [BA41-BA43] [112]
Vorapaxar DMA16BR Moderate Increased risk of bleeding by the combination of Fluoxetine and Vorapaxar. Myocardial infarction [BA41-BA43] [112]
Tirofiban DMQG17S Moderate Increased risk of bleeding by the combination of Fluoxetine and Tirofiban. Myocardial infarction [BA41-BA43] [112]
Promethazine DM6I5GR Moderate Additive antidopaminergic effects by the combination of Fluoxetine and Promethazine. Nausea/vomiting [MD90] [151]
Rolapitant DM8XP26 Moderate Decreased metabolism of Fluoxetine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [168]
Granisetron DMIUW25 Major Additive serotonergic effects by the combination of Fluoxetine and Granisetron. Nausea/vomiting [MD90] [95]
Dolasetron DMMG26Z Major Additive serotonergic effects by the combination of Fluoxetine and Dolasetron. Nausea/vomiting [MD90] [95]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Fluoxetine and Ondansetron. Nausea/vomiting [MD90] [95]
E-2007 DMJDYNQ Moderate Antagonize the effect of Fluoxetine when combined with E-2007. Neuropathy [8C0Z] [120]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Fluoxetine and Bupropion. Nicotine use disorder [6C4A] [95]
Entrectinib DMMPTLH Moderate Decreased metabolism of Fluoxetine caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [111]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Fluoxetine and Sibutramine. Obesity [5B80-5B81] [169]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Fluoxetine and Lorcaserin. Obesity [5B80-5B81] [170]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Fluoxetine and Dexfenfluramine. Obesity [5B80-5B81] [98]
Metolazone DMB39LO Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Metolazone. Oedema [MG29] [114]
Polythiazide DMCH80F Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Polythiazide. Oedema [MG29] [114]
Urea DMUK75B Moderate Increased risk of hyponatremia by the combination of Fluoxetine and Urea. Oesophagitis [DA24] [114]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Fluoxetine and Levomethadyl Acetate. Opioid use disorder [6C43] [107]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Fluoxetine and Lofexidine. Opioid use disorder [6C43] [95]
Diclofenac DMPIHLS Moderate Increased risk of bleeding by the combination of Fluoxetine and Diclofenac. Osteoarthritis [FA00-FA05] [112]
Naproxen DMZ5RGV Moderate Increased risk of bleeding by the combination of Fluoxetine and Naproxen. Osteoarthritis [FA00-FA05] [112]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Rucaparib. Ovarian cancer [2C73] [95]
Pentazocine DM1XBHS Major Additive serotonergic effects by the combination of Fluoxetine and Pentazocine. Pain [MG30-MG3Z] [98]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Fluoxetine and Dextropropoxyphene. Pain [MG30-MG3Z] [171]
Butorphanol DM5KYPJ Moderate Additive CNS depression effects by the combination of Fluoxetine and Butorphanol. Pain [MG30-MG3Z] [125]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Fluoxetine and Oxymorphone. Pain [MG30-MG3Z] [125]
Aspirin DM672AH Moderate Increased risk of bleeding by the combination of Fluoxetine and Aspirin. Pain [MG30-MG3Z] [149]
Etodolac DM6WJO9 Moderate Increased risk of bleeding by the combination of Fluoxetine and Etodolac. Pain [MG30-MG3Z] [112]
Diflunisal DM7EN8I Moderate Increased risk of bleeding by the combination of Fluoxetine and Diflunisal. Pain [MG30-MG3Z] [112]
Ibuprofen DM8VCBE Moderate Increased risk of bleeding by the combination of Fluoxetine and Ibuprofen. Pain [MG30-MG3Z] [112]
Levorphanol DMGS80V Moderate Additive CNS depression effects by the combination of Fluoxetine and Levorphanol. Pain [MG30-MG3Z] [125]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Fluoxetine and Dezocine. Pain [MG30-MG3Z] [125]
Nalbuphine DMOSQGU Moderate Additive CNS depression effects by the combination of Fluoxetine and Nalbuphine. Pain [MG30-MG3Z] [125]
Buprenorphine DMPRI8G Moderate Additive CNS depression effects by the combination of Fluoxetine and Buprenorphine. Pain [MG30-MG3Z] [125]
Hydrocodone DMQ2JO5 Moderate Additive CNS depression effects by the combination of Fluoxetine and Hydrocodone. Pain [MG30-MG3Z] [125]
Piroxicam DMTK234 Moderate Increased risk of bleeding by the combination of Fluoxetine and Piroxicam. Pain [MG30-MG3Z] [112]
Oxycodone DMXLKHV Moderate Additive CNS depression effects by the combination of Fluoxetine and Oxycodone. Pain [MG30-MG3Z] [125]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Triclabendazole. Parasitic worm infestation [1F90] [95]
Safinamide DM0YWJC Moderate Additive serotonergic effects by the combination of Fluoxetine and Safinamide. Parkinsonism [8A00] [166]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Fluoxetine and Rasagiline. Parkinsonism [8A00] [99]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Pimavanserin. Parkinsonism [8A00] [172]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Fluoxetine and Macimorelin. Pituitary gland disorder [5A60-5A61] [173]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Fluoxetine and Lefamulin. Pneumonia [CA40] [174]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Fluoxetine and Choline salicylate. Postoperative inflammation [1A00-CA43] [112]
Bromfenac DMKB79O Moderate Increased risk of bleeding by the combination of Fluoxetine and Bromfenac. Postoperative inflammation [1A00-CA43] [112]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Fluoxetine and Ritodrine. Preterm labour/delivery [JB00] [116]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Degarelix. Prostate cancer [2C82] [107]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Fluoxetine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [175]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Nilutamide. Prostate cancer [2C82] [107]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Enzalutamide. Prostate cancer [2C82] [107]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Flutamide. Prostate cancer [2C82] [107]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Relugolix. Prostate cancer [2C82] [107]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Bicalutamide. Prostate cancer [2C82] [107]
Tamsulosin DM5QF9V Moderate Decreased metabolism of Fluoxetine caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [176]
Levomepromazine DMIKFEL Moderate Decreased metabolism of Fluoxetine caused by Levomepromazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [151]
Fluphenazine DMIT8LX Moderate Decreased metabolism of Fluoxetine caused by Fluphenazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [151]
Triflupromazine DMKFQJP Moderate Additive antidopaminergic effects by the combination of Fluoxetine and Triflupromazine. Psychotic disorder [6A20-6A25] [151]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Fluoxetine and Epoprostenol. Pulmonary hypertension [BB01] [112]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Fluoxetine and Iloprost. Pulmonary hypertension [BB01] [112]
Everolimus DM8X2EH Moderate Decreased metabolism of Fluoxetine caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [177]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Fluoxetine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [178]
Meloxicam DM2AR7L Moderate Increased risk of bleeding by the combination of Fluoxetine and Meloxicam. Rheumatoid arthritis [FA20] [112]
Sulindac DM2QHZU Moderate Increased risk of bleeding by the combination of Fluoxetine and Sulindac. Rheumatoid arthritis [FA20] [112]
Celecoxib DM6LOQU Moderate Decreased metabolism of Fluoxetine caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [179]
Oxaprozin DM9UB0P Moderate Increased risk of bleeding by the combination of Fluoxetine and Oxaprozin. Rheumatoid arthritis [FA20] [112]
Flurbiprofen DMGN4BY Moderate Increased risk of bleeding by the combination of Fluoxetine and Flurbiprofen. Rheumatoid arthritis [FA20] [112]
Fenoprofen DML5VQ0 Moderate Increased risk of bleeding by the combination of Fluoxetine and Fenoprofen. Rheumatoid arthritis [FA20] [112]
Tolmetin DMWUIJE Moderate Increased risk of bleeding by the combination of Fluoxetine and Tolmetin. Rheumatoid arthritis [FA20] [112]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Fluoxetine and Mesoridazine. Schizophrenia [6A20] [95]
Thioridazine DM35M8J Major Decreased metabolism of Fluoxetine caused by Thioridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [180]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Fluoxetine caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [181]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Fluoxetine and Iloperidone. Schizophrenia [6A20] [95]
Haloperidol DM96SE0 Moderate Decreased metabolism of Fluoxetine caused by Haloperidol mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [151]
Perphenazine DMA4MRX Moderate Additive antidopaminergic effects by the combination of Fluoxetine and Perphenazine. Schizophrenia [6A20] [151]
Chlorpromazine DMBGZI3 Moderate Decreased metabolism of Fluoxetine caused by Chlorpromazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [151]
Trifluoperazine DMKBYWI Moderate Additive antidopaminergic effects by the combination of Fluoxetine and Trifluoperazine. Schizophrenia [6A20] [151]
Risperidone DMN6DXL Moderate Additive antidopaminergic effects by the combination of Fluoxetine and Risperidone. Schizophrenia [6A20] [151]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Fluoxetine and Amisulpride. Schizophrenia [6A20] [182]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Asenapine. Schizophrenia [6A20] [95]
Pimozide DMW83TP Major Decreased metabolism of Fluoxetine caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [183]
Salicyclic acid DM2F8XZ Moderate Increased risk of bleeding by the combination of Fluoxetine and Salicyclic acid. Seborrhoeic dermatitis [EA81] [149]
Fentanyl DM8WAHT Major Additive serotonergic effects by the combination of Fluoxetine and Fentanyl. Sensation disturbance [MB40] [98]
Sufentanil DMU7YEL Major Additive serotonergic effects by the combination of Fluoxetine and Sufentanil. Sensation disturbance [MB40] [98]
Vardenafil DMTBGW8 Moderate Decreased metabolism of Fluoxetine caused by Vardenafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [184]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Fluoxetine and LEE011. Solid tumour/cancer [2A00-2F9Z] [95]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Fluoxetine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [95]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [107]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [95]
Pitolisant DM8RFNJ Major Decreased metabolism of Fluoxetine caused by Pitolisant mediated inhibition of CYP450 enzyme. Somnolence [MG42] [107]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [95]
Warfarin DMJYCVW Moderate Decreased metabolism of Fluoxetine caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [126]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Fluoxetine and Adenosine. Supraventricular tachyarrhythmia [BC81] [95]
Plicamycin DM7C8YV Moderate Increased risk of bleeding by the combination of Fluoxetine and Plicamycin. Testicular cancer [2C80] [112]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Fluoxetine and Caplacizumab. Thrombocytopenia [3B64] [112]
Apixaban DM89JLN Moderate Increased risk of bleeding by the combination of Fluoxetine and Apixaban. Thrombosis [DB61-GB90] [112]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Fluoxetine and Cangrelor. Thrombosis [DB61-GB90] [112]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Fluoxetine and Brilinta. Thrombosis [DB61-GB90] [112]
Clopidogrel DMOL54H Major Decreased metabolism of Fluoxetine caused by Clopidogrel mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [185]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Lenvatinib. Thyroid cancer [2D10] [95]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Fluoxetine and Cabozantinib. Thyroid cancer [2D10] [107]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Fluoxetine and Papaverine. Tonus and reflex abnormality [MB47] [186]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Fluoxetine and Tizanidine. Tonus and reflex abnormality [MB47] [187]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Fluoxetine and Tacrolimus. Transplant rejection [NE84] [95]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Fluoxetine and Tolbutamide. Type 2 diabetes mellitus [5A11] [104]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Fluoxetine and Chlorpropamide. Type 2 diabetes mellitus [5A11] [104]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Fluoxetine and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [104]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Fluoxetine and Insulin degludec. Type-1/2 diabete [5A10-5A11] [104]
Astemizole DM2HN6Q Major Decreased metabolism of Fluoxetine caused by Astemizole mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [188]
Methdilazine DMAUHQX Moderate Decreased metabolism of Fluoxetine caused by Methdilazine mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [151]
Trimeprazine DMEMV9D Moderate Additive antidopaminergic effects by the combination of Fluoxetine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [189]
Betrixaban DM2C4RF Moderate Increased risk of bleeding by the combination of Fluoxetine and Betrixaban. Venous thromboembolism [BD72] [112]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Fluoxetine and Procainamide. Ventricular tachyarrhythmia [BC71] [95]
Propafenone DMPIBJK Moderate Decreased metabolism of Fluoxetine caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [190]
Flecainide DMSQDLE Moderate Decreased metabolism of Fluoxetine caused by Flecainide mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [190]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Fluoxetine and Amiodarone. Ventricular tachyarrhythmia [BC71] [95]
⏷ Show the Full List of 325 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Aminoethanoic acid E00025 750 Buffering agent; Disintegrant; Lyophilization aid
Benzoic acid E00009 243 Antimicrobial preservative
Butylparaben E00142 7184 Antimicrobial preservative
D&C red no. 28 E00491 6097185 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
methylparaben E00149 7456 Antimicrobial preservative
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Food blue 1 aluminum lake E00512 11979396 Colorant
Simethicone E00575 6433516 Antifoaming agent; Diluent; Water-repelling agent
Ammonia E00007 222 Alkalizing agent
Brushite E00392 104805 Diluent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carboxymethylcellulose sodium E00621 Not Available Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Edetate calcium disodium E00487 6093170 Complexing agent
Eisenoxyd E00585 56841934 Colorant
Ethanol E00023 702 Antimicrobial preservative; Penetration agent; Solvent
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Gelatin E00630 Not Available Other agent
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium propionate E00445 2723816 Antimicrobial preservative
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
Hypromellose acetate succinate E00696 Not Available Coating agent; Solubilizing agent; Modified-release agent;Film/membrane-forming agent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
⏷ Show the Full List of 53 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Fluoxetine 10 mg tablet 10 mg Oral Tablet Oral
Fluoxetine 20 mg tablet 20 mg Oral Tablet Oral
Fluoxetine 10 mg capsule 10 mg Oral Capsule Oral
Fluoxetine 20 mg capsule 20 mg Oral Capsule Oral
Fluoxetine 90 mg capsule 90 mg Delayed Release Oral Capsule Oral
Fluoxetine 40 mg capsule 40 mg Oral Capsule Oral
Fluoxetine 60 mg tablet 60 mg Oral Tablet Oral
Fluoxetine Hydrochloride eq 20mg base tablet eq 20mg base Tablet Oral
Fluoxetine Hydrochloride eq 20mg base capsule eq 20mg base Capsule Oral
Fluoxetine 16 mg tablet 16 mg Chewable Tablet Oral
Fluoxetine 32 mg tablet 32 mg Chewable Tablet Oral
Fluoxetine 64 mg tablet 64 mg Chewable Tablet Oral
Fluoxetine 8 mg tablet 8 mg Chewable Tablet Oral
Fluoxetine Hydrochloride eq 20mg base/5ml solution eq 20mg base/5ml Solution Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 203).
2 Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci. 2008 Apr;29(4):208-17.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Fluoxetine and reversal of multidrug resistance. Cancer Lett. 2006 Jun 18;237(2):180-7.
8 O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes. J Pharmacol Exp Ther. 2002 Jan;300(1):105-11.
9 Antidepressant drugs in the elderly--role of the cytochrome P450 2D6. World J Biol Psychiatry. 2003 Apr;4(2):74-80.
10 (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91.
11 Binding of CYP2C9 with diverse drugs and its implications for metabolic mechanism. Med Chem. 2009 May;5(3):263-70.
12 Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes. Acta Pharmacol Sin. 2001 Jan;22(1):85-90.
13 Clinically significant psychotropic drug-drug interactions in the primary care setting. Curr Psychiatry Rep. 2012 Aug;14(4):376-90.
14 Molecular characterization of CYP2B6 substrates. Curr Drug Metab. 2008 Jun;9(5):363-73.
15 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
16 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
17 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
18 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
19 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
20 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
21 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
22 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
23 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
24 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
25 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
26 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
27 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
28 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
29 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
30 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
31 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
32 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
33 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
34 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
35 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
36 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
37 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
38 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
39 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
40 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
41 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
42 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
43 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
44 Drug Interactions Flockhart Table
45 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
46 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
47 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
48 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
49 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
50 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
51 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
52 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
53 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
54 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
55 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
56 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
57 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
58 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
59 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
60 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
61 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
62 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
63 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
64 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
65 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
66 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
67 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
68 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
69 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
70 Drugs that may have potential CYP2B6 interactions.
71 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
72 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
73 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
74 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
75 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
76 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
77 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
78 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
79 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
80 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
81 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
82 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
83 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
84 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
85 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
86 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
87 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
88 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
89 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
90 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
91 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
92 Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
93 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
94 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
95 Canadian Pharmacists Association.
96 Aranow AB, Hudson JI, Pope HG, et al "Elevated antidepressant plasma levels after addition of fluoxetine." Am J Psychiatry 146 (1989): 911-3. [PMID: 2787124]
97 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
98 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
99 Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20. [PMID: 8227489]
100 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
101 Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
102 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
103 Elyazigi A, Chaleby K, Gad A, Raines DA "Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone." J Clin Pharmacol 35 (1995): 17-21. [PMID: 7751409]
104 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
105 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
106 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
107 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
108 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
109 Product Information. Reminyl (galantamine) Janssen Pharmaceuticals, Titusville, NJ.
110 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
111 Cerner Multum, Inc. "Australian Product Information.".
112 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
113 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
114 Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
115 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
116 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
117 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
118 Lee DO, Lee CD "Serotonin syndrome in a child associated with erythromycin and sertraline." Pharmacotherapy 19 (1999): 894-6. [PMID: 10417041]
119 Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
120 Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
121 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
122 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
123 Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
124 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
125 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
126 Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7. [PMID: 2198298]
127 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
128 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
129 Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA "The influence of CYP2d6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans." Clin Pharmacol Ther 60 (1996): 295-307. [PMID: 8841152]
130 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
131 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
132 Product Information. Xenazine (tetrabenazine). Prestwick Pharmaceuticals Inc, Washington DC, VA.
133 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
134 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
135 Jalil P "Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports." J Neurol Neurosurg Psychiatry 55 (1992): 412-3. [PMID: 1602320]
136 Dursun SM, Mathew VM, Reveley MA "Toxic serotonin syndrome after fluoxetine plus carbamazepine." Lancet 342 (1993): 442-3. [PMID: 8101947]
137 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
138 Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
139 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
140 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
141 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
142 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
143 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
144 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
145 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
146 Ouellet D, Hsu A, Qian J, Lamm JE, Cavanaugh JH, Leonard JM, Granneman GR "Effect of fluoxetine on pharmacokinetics of ritonavir." Antimicrob Agents Chemother 42 (1998): 3107-12. [PMID: 9835499]
147 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
148 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
149 Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
150 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
151 Avenoso A, Spina E, Campo G, Facciola G, Ferlito M, Zuccaro P, Perucca E, Caputi AP "Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications." Pharmacol Res 35 (1997): 335-9. [PMID: 9264051]
152 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
153 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
154 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
155 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
156 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
157 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
158 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
159 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
160 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
161 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
162 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
163 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
164 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
165 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
166 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
167 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
168 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
169 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
170 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
171 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
172 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
173 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
174 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
175 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
176 Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
177 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
178 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
179 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
180 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
181 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
182 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
183 Ahmed I, Dagincourt PG, Miller LG, Shader RI "Possible interaction between fluoxetine and pimozide causing sinus bradycardia." Can J Psychiatry 38 (1993): 62-3. [PMID: 8448725]
184 Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
185 Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]
186 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
187 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
188 Marchiando RJ, Cook MD "Probable terfenadine-fluoxetine-associated cardiac toxicity." Ann Pharmacother 29 (1995): 937-8. [PMID: 8547749]
189 Dsouza DC, Bennett A, Abidargham A, Krystal JH "Precipitation of a psychoneuromotor syndrome by fluoxetine in a haloperidol-treated schizophrenic patient." J Clin Psychopharmacol 14 (1994): 361-3. [PMID: 7806697]
190 Alfaro CL, Lam YWF, Simpson J, Ereshefsky L "CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline." J Clin Psychopharmacol 19 (1999): 155-63. [PMID: 10211917]